日本监管机构已授予万达生物制药旗下在研药物Imsidolimab孤儿药资格,用于治疗泛发性脓疱型银屑病。
这一认定旨在鼓励针对罕见疾病的药物开发,可能为该药未来在日本市场的审批与商业化提供路径支持。
日本监管机构已授予万达生物制药旗下在研药物Imsidolimab孤儿药资格,用于治疗泛发性脓疱型银屑病。
这一认定旨在鼓励针对罕见疾病的药物开发,可能为该药未来在日本市场的审批与商业化提供路径支持。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.